SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Despite strong earnings and positive AI outlook, Broadcom (AVGO) is trending down, driven by concerns over margin compression and a broader tech sector pullback. Community chatter highlights disappointment in the stock's reaction to earnings, with some suspecting market manipulation and a potential AI bubble. Investors are debating whether to buy the dip or brace for further declines, while analysts remain largely bullish on the stock's long-term potential.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending with community members highlighting a significant volume spike and debating potential price targets. Some traders are drawing comparisons to other stocks with similar trading patterns, while others warn of potential "pump and dump" schemes associated with Chinese stocks. The stock's connection to robotics and its small float are also being discussed as potential catalysts.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that the U.S. government might reclassify marijuana, potentially easing restrictions for cannabis companies. Community discussions revolve around the timing and impact of a possible executive order, with some bracing for a "sell-the-news" event. Others are optimistic, pointing to potential tax relief and increased investment in the cannabis sector.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to positive interim data from its RAD 101 Phase 2b imaging trial, igniting excitement about its potential in brain metastases diagnosis. Bullish community members anticipate a short squeeze and are targeting higher price levels, while others urge caution, citing potential dilution and the need for further confirmation. The focus remains on RADX's low float and upcoming catalysts, particularly related to its oncology pipeline.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco's stock is trending downwards, sparking community concern and speculation about potential bounce points and shorting opportunities. A Roth Capital downgrade, citing concerns over membership growth and competition, appears to be a catalyst for the negative sentiment. Despite some bullish arguments around long-term value and recurring membership revenue, the community is focused on the immediate price action.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending amid community chatter about a potential short squeeze, with comparisons being drawn to other low-float runners. The stock's price action and thin float are fueling speculation, as traders closely monitor key levels for potential breakouts. Some caution exists due to the company's non-US location.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

GLSI is trending as traders discuss potential short squeezes and speculate about upcoming catalysts. Community members are analyzing the stock's high short interest and the potential for explosive moves, while also noting that recent cutting approval red tape could be good for approval application. Some are questioning the timing of news and its impact on price movement.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as investors react to reports of a potential executive order from President Trump to reclassify marijuana, with discussions focusing on the potential impact on cannabis businesses and the broader sector. Community members are debating whether to buy now or wait for a dip, while also considering how the potential reclassification will affect US cannabis companies versus Canadian LPs. Some are also awaiting a Supreme Court decision and remain skeptical until the executive order is officially signed.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending as investors assess the implications of its AI strategy and recent partnerships, with community discussions focusing on whether the company can maintain its growth trajectory amidst rising competition. Recent reports of a potential acquisition of cybersecurity firm Armis for $7B has sparked debate about valuation and strategic fit, contributing to market volatility. Despite long-term bullish sentiment from analysts, the stock's YTD performance has some questioning its current valuation and potential for short-term recovery.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending amid discussions about its potential within the AI infrastructure landscape and recent market volatility affecting data center stocks. The community is actively debating whether the stock's current price reflects its long-term growth prospects, especially in light of its Microsoft deal, and the broader implications of an AI "bubble". Sentiment is mixed, with some viewing the recent dip as a buying opportunity and others expressing concern over the company's valuation and short-term performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Allarity Therapeutics, Inc. (ALLR) on Tuesday announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Stenoparib. Following the announcement, shares of the company more than doubled in value by Tuesday afternoon.Stenoparib is an investigational treatment for patients with advanced ovarian cancer. FDA’s Fast Track designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need. It allows for more frequent interactions with the FDA throughout the drug development process and potentially provides eligibility for accelerated approval and priority review, upon meeting relevant criteria.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALLR">ALLR stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_26_at_12_16_43_PM_png_5d0f99e451.webp" alt="ALLR's Sentiment Meter and Message Volume as of 12:17 p.m. ET on Aug. 26, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>ALLR's Sentiment Meter and Message Volume as of 12:17 p.m. ET on Aug. 26, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed surprise at the rally and opined that the stock might drop to below $1 by the end of the day.<stembedurl>https://stocktwits.com/patb99/message/626594104</stembedurl>Another user stated that larger pharmaceutical companies will now be interested in the drug.<stembedurl>https://stocktwits.com/Creyedr/message/626587898</stembedurl>Allarity CEO Thomas Jensen <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/26/3139198/0/en/Allarity-Therapeutics-Granted-FDA-Fast-Track-Designation-for-Stenoparib-for-the-Treatment-of-Advanced-Ovarian-Cancer.html">said</a> the company is pleased with the designation. “We look forward to engaging closely with the FDA as we advance this program,” he added.US-headquartered Allarity started patient enrollment under a new mid-stage clinical trial protocol evaluating Stenoparib in advanced, recurrent, platinum-resistant, or platinum-ineligible ovarian cancer in early June 2025. Several patients have already been dosed in the study. The trial is designed to accelerate clinical development of Stenoparib. Previous mid-stage study data showed durable clinical benefit for Stenoparib.The therapy was originally developed by Eisai Co., but Allarity secured exclusive global rights for the development and commercialization.ALLR stock has gained 74% this year but has lost 59% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-stock-rallies-after-therapy-for-autoimmune-disease-meets-late-stage-trial-goals/chsvb4wRdjv">Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Allarity Therapeutics Stock Double In Value Today?

The company’s Stenoparib, an investigational treatment for patients with advanced ovarian cancer, was granted the Fast Track designation by the FDA.

Equity

ReShape Lifesciences Inc. (1,900% Jump in Message Volume)ReShape Lifesciences saw a surge in retail discussion as traders speculated on the potential approval of its proposed reverse merger with Vyome Therapeutics, first announced in June 2024.&nbsp;The metabolic health solutions company stated in January that it was still working with the SEC on its S-4 filing and would set a shareholder meeting date once the filing is declared effective.Some investor interest also stemmed from reports that Michael Bigger’s fund had taken a significant stake in ReShape. However, sentiment remained mixed after the company raised $6 million through a public offering last month.&nbsp;ReShape’s stock is down nearly 80% year-to-date (YTD).Allarity Therapeutics Inc. (1,700% Jump in Message Volume)Allarity drew attention after announcing a Phase 2 trial evaluating the combination of stenoparib, a PARP inhibitor, with the chemotherapy agent temozolomide for treating recurrent small-cell lung cancer (SCLS). Prior studies had shown about a 40% response rate in SCLC patients, but dose-limiting toxicity remained a challenge.Additionally, Allarity’s Board of Directors authorized a $5 million share repurchase program on Monday, allowing buybacks through February 2026.&nbsp;The stock is down over 9% YTD.Exact Sciences Corporation (1,100% Jump in Message Volume)Exact Sciences, known for its cancer diagnostics, saw increased interest as it participated in the TD Cowen 45th Annual Healthcare Conference and Raymond James &amp; Associates’ 46th Annual Institutional Investors Conference last week.&nbsp;The company reiterated its plans to launch three new cancer screening tests in 2025, including Cologuard Plus (a next-generation colorectal cancer screening test), Oncodetect (a molecular residual disease test) and Cancerguard (a multi-cancer screening test).The company noted rising demand for rescreens, which grew 30% last year and are expected to grow another 30% this year.&nbsp;Exact Sciences’ stock is down over 18% YTD.CVS Health Corporation (700% Jump in Message Volume)CVS Health made headlines last week after announcing that Wellvana had acquired its Medicare Shared Savings Program business in an all-stock deal, giving CVS a strategic minority stake in Wellvana.On Saturday, The Wall Street Journal <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/retail/cvs-small-store-openings-b0e196a2">reported</a> that CVS plans to open a dozen new stores focused on full-service pharmacies with minimal retail space, a shift in response to declining retail sales across drugstore chains.&nbsp;The stock has gained 47% YTD.AbbVie Inc. (500% Jump in Message Volume)AbbVie’s stock gained traction after BofA raised its price target to $223 from $200, maintaining a ‘Neutral’ rating. The bullish revision followed AbbVie’s $350 million upfront deal with Gubra to develop GUB014295, a long-acting amylin analog targeting obesity.Under the agreement, Gubra could receive up to $1.88 billion in milestone payments, plus tiered royalties on global net sales.&nbsp;AbbVie shares are up nearly 20% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a  Medicare business deal, and an obesity drug partnership sparked buzz among Stocktwits users for the week ended March 7, 2025.

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

ALLR
Allarity Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ALLR News

ALLRAllarity Therapeutics Inc